A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Intra-Articular Allocetra in Patients with Primary Knee Osteoarthritis
Condition studied
Knee Osteoarthritis
Investigational medicinal product(s)
Eligibility
Primary endpoint
The change from baseline of the WOMAC Pain score at 3 months between Allocetra and Placebo., The change from baseline for the WOMAC Function score at 3 months., Incidence and severity of Adverse Events (AEs), treatment disruptions/ discontinuations and evaluation of safety laboratory values up to 6 months.
Endpoint detail
The change from baseline of the WOMAC Pain score at 6 months., The change from baseline of the WOMAC Function score at 6 months., The change from baseline for the WOMAC Total score at 3 months., The change from baseline of the WOMAC Total score at 6 months., The change from baseline of the Average Daily Pain Numerical Rating Scale (ADP-NRS) at 3 months., The change from baseline of the ADP-NRS at 6 months.
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View 2025-524668-39-00 on CTIS ↗ ← All trials in the EU